Lupin posted a 52% rise in net profit at ₹1,221 crore for Q1 FY25.
The growth was driven by increased sales in the US and cost optimization.
Strong performance highlights Lupin’s strategic focus on high-margin markets.
Drug maker Lupin on Tuesday posted a 52% year-on-year increase in consolidated profit after tax at ₹1,221 crore in the June quarter, driven by strong sales in the US and India.
The drug maker reported a profit after tax (PAT) of ₹805 crore in the April-June quarter of last fiscal.
Sales rose to ₹6,164 crore in the first quarter as against ₹5,514 crore in the year-ago period, Lupin Ltd said in a statement.
We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments," Lupin MD Nilesh Gupta said.
"As we begin the year, our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth," he added.
The company said its sales in the US stood at ₹2,404 crore in the June quarter, registering a growth of 24% as compared to ₹1,934 crore in the year-ago period.
India sales for Q1 FY26 stood at ₹2,089 crore, up 8% from ₹1,938 crore.
